Bukwang Pharma 
Welcome,         Profile    Billing    Logout  
 5 Products   33 Diseases  5 Products   852 Trials   3470 News 
901 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AiTan (rivoceranib) / HLB Bio Group
ChiCTR-OPN-16009458: A clinical research of Apatinib unite chemotherapy in second-line treatment of advanced lung cancer, gastric cancer and colorectal cancer

Recruiting
4
90
 
combination of apatinib based on the second-line chemotherapy
Suzhou City Hospital; Suzhou City Hospital, self-financing
cancer
 
 
ChiCTR-OPN-16009457: A exploratory controlled clinical study of Apatinib combined TACE in treating advanced hepatocellular carcinoma

Recruiting
4
100
 
Apatinib Mesylate Tablets
the First affiliated Hospital of SooChow University; the First affiliated Hospital of SooChow University, self-financing
cancer
 
 
ChiCTR-OPC-17011020: A clinical research of Apatinib in the treatment of advanced refractory non-small cell lung cancer

Recruiting
4
30
 
Apatinib
101th Hospital of PLA; Level of the institution:, Self-raised funds
NSCLC
 
 
ChiCTR1800015701: A Real-world Study of Apatinib in the treatment for Inoperable or advanced gastric cancer in Shandong

Recruiting
4
1000
 
apatinib
Shandong Cancer Hospital; Jiangsu Hengrui Medicine Co., Ltd., self-financing
Inoperable or advanced gastric cancer
 
 
ChiCTR2000040387: A real-world study of apatinib combined with TACE in patients with advanced liver cancer

Recruiting
4
300
 
apatinib
The First Affiliated Hospital of University of Science and Technology of China; The First Affiliated Hospital of University of Science and Technology of China, self-financing
Intermediate to advanced hepatocellular carcinoma
 
 
ChiCTR2100041973: A prospective, open, single-arm, single-center phase II clinical study of carrelizumab combined with apatinib and tigio capsules in the second-line treatment of patients with metastatic cholangiocarcinoma

Recruiting
4
30
 
Patients with metastatic biliary tract cancer (including gallbladder cancer and cholangiocarcinoma) who have undergone first-line treatment
The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, Self-funded
Cholangiocarcinoma
 
 
ChiCTR2100044694: The prognostic value of PD-L1 in the treatment of advanced hepatocellular carcinoma with combination of apatinib and karelizumab

Recruiting
4
30
 
They were treated with apatinib and karelizumab combined system, without TACE and other local treatment ;The patients with HCC were treated with apatinib and karelizumab combined with TACE
Shandong Provincial Hospital; Shandong Provincial Hospital, China Health Promotion Foundation
Advanced hepatocellular carcinoma
 
 
ChiCTR-OPN-15006601: A prospectiv, multi-center, non-intervention study of Apatinib in the treatment of advanced gastric cancer

Recruiting
4
230
 
apatinib
Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, self-financing
advanced gastric cancer
 
 
ChiCTR-OPN-15007034: A prospective, multi-center study of Apatinib in the treatment of advanced cancer

Recruiting
4
100
 
none
The Second Affiliated Hospital of Soochow University; the Second Affiliated Hospital of Soochow University, self-financing
cancer
 
 
ChiCTR-IPR-15006993: Apatinib as Maintenance Therapy After First-line Chemotherapy (DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer

Not yet recruiting
4
48
 
Apatinib Mesylate Tablets 500 mg qd p.o. ;Best Support Care
Fourth Hospital, Hebei Medical University; Hebei Medical University affiliated Fourth Hospital, self-raise
Gastric Cancer
 
 
ChiCTR-OPC-16010108: The clinical study of Apatinib mesylate combined with Temozolomide in treating patients with recurrent high-grade glioma

Recruiting
4
40
 
Apatinib Mesylate Tablets
the First affiliated Hospital of SooChow University; the First affiliated Hospital of SooChow University, self-financing
cancer
 
 
ChiCTR-OPN-15007443: A prospectiv, single-arm study of Apatinib unite docetaxel in the treatment of advanced squamous cell carcinoma of the lung

Recruiting
4
60
 
Apatinib unite docetaxel
the second people's hospital of lianyungang; The Second People's Hospital of Lianyungang, self-financing
advanced squamous cell carcinoma of the lung
 
 
ChiCTR-OPC-16008295: A observational clinical study of Apatinib combined chemotherapy in the treatment of gastric cancer with AFP positive

Not yet recruiting
4
16
 
combined chemotherapy
Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, self-financing
advanced gastric cancer
 
 
ChiCTR-OPC-16008296: A clinical study of Apatinib combined chemotherapy in the treatment of advanced gastric cancer with malignant peritoneal effusion

Not yet recruiting
4
30
 
combined chemotherapy
Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, self-financing
advanced gastric cancer
 
 
ChiCTR-IPR-16008335: A clinical study of postoperative adjuvant chemotherapy in the treatment of gastric carcinoma unite Apatinib

Not yet recruiting
4
60
 
combined chemotherapy
The People's Liberation Army 101 Hospital; The People's Liberation Army 101 Hospital, self-financing
gastric cancer
 
 
ChiCTR-OPC-16009048: Clinical study of Apatinib Mesylate Tablets in the Second-line treatment of Advanced Squamous Cell Lung Cancer

Recruiting
4
30
 
combined S-1
Anhui Chest Hospital; Anhui Chest Hospital, self-financing
Squamous Cell Lung Cancer
 
 
ChiCTR-OPC-16007953: Clinical study of apatinib mesylate tablets in the treatment of refractory soft tissue sarcoma

Not yet recruiting
4
30
 
Medical and nursing education for patients with soft tissue sarcoma
Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, Henry csco- Cancer Research Fund
Refractory soft tissue sarcoma
 
 
ChiCTR-IPR-15006994: Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells

Not yet recruiting
4
48
 
Apatinib Mesylate Tablets 500 mg qd p.o. ;Best Support Care
Fourth Hospital, Hebei Medical University; Hebei Medical University affiliated Fourth Hospital, self-raise
Gastric Cancer
 
 
ChiCTR-IPR-17010361: First-line randomized, open, controlled clinical trial of EP regimen with sequential apatinib in patients with extensive stage small cell lung cancer

Not yet recruiting
4
120
 
EP, 80mg/ m D1 cisplatin, etoposide 100mg/ square meters, D1-3, apatinib mesylate tablets: 500 or 750 mg QD Po, D4 to the next cycle of twenty-first days, 4 weeks for 1 cycles, 2 cycles of evaluation time, 6 cycle withdrawal. ;EP, 80mg/ m D1 cisplatin, etoposide 100mg/ square meters, D1-3, cycle of twenty-first days, 4 weeks for 1 cycles, 2 cycles of evaluation time, 6 cycle withdrawal.
The North Hospital of the Affiliated Hospital of Qiingdao University hospital; The North Hospital of the Affiliated Hospital of Qiingdao University hospital, CSCO Fund / Jiangsu Hengrui Medicine Co. Ltd.
extensive stage small cell lung cancer
 
 
ChiCTR-OPC-16009849: A study to determine the curative effect and mechanism of Apatinib combined with chemotherapy for SD patients with advanced malignant solid tumor

Recruiting
4
100
 
Apatinib Mesylate Tablets
the First affiliated Hospital of SooChow University; the First affiliated Hospital of SooChow University, self-financing
cancer
 
 
ChiCTR-OPC-17013834: Clinical study of Apatinib combined with docetaxel as second-line treatment in advanced gastric cancer

Recruiting
4
20
 
Apatinib combined with Docetaxel
Shanxi Tumor Hospital; Shanxi Tumor Hospital, Chinese Anti-Cancer Association- HengRui pharmaceutical innovative medicine clinical research fund
gastric cancer
 
 
ChiCTR-OPC-17011019: An opening, single arm study of Apatinib in the treatment of advanced hepatocellular carcinoma

Recruiting
4
60
 
Apatinib
Huai'an First People's Hospital, Nanjing Medical University; Huai'an First People's Hospital, Nanjing Medical University, Jiangsu Hengrui Medicine Co., Ltd.
hepatocellular carcinoma
 
 
ChiCTR-OPC-17011376: The clinical research of Apatinib for the treatment of advanced non-small cell lung cancer

Recruiting
4
30
 
Apatinib
the First affiliated Hospital of SooChow University; the First affiliated Hospital of SooChow University, self-financing
cancer
 
 
ChiCTR-OPC-17011378: The clinical observational study of Apatinib 425mg Joint docetaxel for the second-line treatment of advanced lung squamous carcinoma

Recruiting
4
30
 
Apatinib +docetaxel
the First affiliated Hospital of SooChow University; the First affiliated Hospital of SooChow University, self-financing
cancer
 
 
ChiCTR-OPC-16008637: A Study of Second-line Treatment With Apatinib and S-1 in Advanced Hepatocellular Carcinoma Patients

Recruiting
4
120
 
Apatinib 500mg/day ;Apatinib 750mg/day ;S-1
the First Affiliated Hospital of Zhengzhou University; the First Affiliated Hospital of Zhengzhou University, CSCO- Henry Cancer Research Fund
Advanced Hepatocellular
 
 
ChiCTR-OPC-16009894: Exploratory clinical study of apatinib mesylate tablets in the treatment of EGFR negative patients with non squamous non-small cell lung cancer.

Recruiting
4
40
 
Apatinib + cisplatin + docetaxel ;cisplatin + docetaxel
The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University, raise independently
lung cancer
 
 
ChiCTR-OPC-17011822: A clinical study of Apatinib combined TACE in treating intermediate and advanced hepatocellular carcinoma

Recruiting
4
100
 
Apatinib+TACE
the First affiliated Hospital of SooChow University; the First affiliated Hospital of SooChow University, self-financing
cancer
 
 
ChiCTR-OPC-17010714: Apatinib Mesylate Tablets of joint mFOLFOX6 neoadjuant chemotherapy in locally advanced colorectal cancer clinical research

Recruiting
4
60
 
Apatinib Mesylate Tablets of joint mFOLFOX6 neoadjuant chemotherapy
Tianjin people's hospital; Tianjin people's hospital, Jiang Su Heng Rui medicine. co.LTD
Colorectal cancer
 
 
ChiCTR1800015202: Clinical study of Apatinib combined with chemotherapy or single Drug for second-line treatment failure in advanced ovarian cancer

Not yet recruiting
4
30
 
Apatinib combined with conventional chemotherapy regimen
Yibin second people's Hospital; Yibin second people's Hospital, Self financing
ovarian cancer
 
 
ChiCTR-OIC-16008894: Taxanes combined with Apatinib mesylate in the treatment for patients with advanced breast cancer: an open-label, single-arm, single-center clinical research

Recruiting
4
30
 
Apatinib 500mg/day
The First Hospital of Lanzhou Uiversity; The First Hospital of Lanzhou University, self-financing
advanced breast cancer
 
 
ChiCTR-OPC-17011722: An open and one-armed exploration of Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-small Cell Lung Cancer

Recruiting
4
80
 
Apatinib+Docetaxel
The First Affiliated Hospital Of Nanchang University; The First Affiliated Hospital Of Nanchang University, self-financing
cancer
 
 
ChiCTR-OPC-16009725: Apatinib as Adjuvant Treatment in the Recurrence of Hepatocellular Carcinoma

Recruiting
4
40
 
Apatinib 250mg/Day
Nanjing Drum Tower Hospital; Nanjing Drum Tower Hospital, self-financing
Hepatocellular carcinoma
 
 
ChiCTR-OPN-17013220: An open-label, single-arm, prospective study of TACE combined with apatinib for unresectable liver metastases from colorectal cancer

Recruiting
4
20
 
TACE combined with apatinib
Yueyang Hospital of integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Mesdicne; Yueyang Hospital of integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Mesdicne, self-raised
colorectal liver metastases
 
 
ChiCTR-OPN-17013304: Clinical study of first-line therapy with Apatinib Mesylate in combination with chemotherapy for EGFR-negative advanced non-small cell lung cancer

Recruiting
4
60
 
Apatinib + Docetaxel + Platinum; Docetaxel + Platinum
2nd People's Hospital of Fuyang City; 2nd People's Hospital of Fuyang City, self-financing
NSCLC
 
 
ChiCTR1800020145: Open, single-arm, exploratory study for apatinib mesylate in the treatment of recurrent glioma

Completed
4
32
 
Patients were treated with temozolomide combined with apatinib
Sanbo Brain Hospital, Capital Medical University; Sanbo Brain Hospital, Capital Medical Universit, Jiangsu hengrui pharmaceutical co., LTD
glioma
 
 
ChiCTR-OPC-17010758: Mesylate apatinib combined with chemotherapy in the treatment of clinical study of osteosarcoma recurrence and metastasis

Recruiting
4
40
 
Apatinib or apatinib + chemotherapy
Xijing Hospital affiliated to The Fourth Military Medical University; Xijing Hospital affiliated to The Fourth Military Medical University, 经费自筹 Self financing
osteosarcoma
 
 
ChiCTR-OPC-17012186: An prospective, single-arm, multi-center clinical trial of Apatinib combined with capecitabine in the treatment of advanced ovarian cancer

Recruiting
4
30
 
combined Capecitabine
The Second People's Hospital of Hefei; The Second People's Hospital of Hefei, self-financing
Ovarian cancer
 
 
ChiCTR-OPC-17010671: Clinical study of combined use of apatinib in patients with locally advanced cervical cancer during concurrent radiotherapy and chemotherapy

Not yet recruiting
4
30
 
Apatinib + cisplatin + radiotherapy
Qinghai Red Cross Hospital; Qinghai Red Cross Hospital, Self financing
locally advanced cervical carcinoma
 
 
ChiCTR-OPN-17011652: A clinical study of recurrent ovarian ovarian cancer in the treatment of platinum resistance in apatinib tablet

Not yet recruiting
4
280
 
Apatinib + chemotherapy ;Pure chemotherapy
Xijing Hospital affiliated to The Fourth Military Medical University; Xijing Hospital affiliated to The Fourth Military Medical University, Self financing
Late-stage platinum resistant ovarian cancer
 
 
ChiCTR-OPC-17010572: Clinical study of adenocarcinoma with apatinib mesylate tablets combined with chemotherapy as second-line treatment of advanced gastric cancer or gastric esophagus

Not yet recruiting
4
100
 
limit into the grop and the ruled out
Yangzhong People's Hospital; Yangzhong People's Hospital, self-raised
gastric cancer
 
 
ChiCTR1800015308: A multi-center single arm study of FOLFIRI combined with Apatinib on the treatment of non resectable metastatic colorectal cancer

Recruiting
4
40
 
FOLFIRI combined with apatinib
Shanxi Tumor Hospital; Shanxi Tumor Hospital, Chinese Anti-Cancer Association- HengRui pharmaceutical innovative medicine clinical research fund
advanced colorectal cancer
 
 
ChiCTR1800015494: Clinical study of apatinib mesylate tablets combined with chemotherapy in the treatment of platinum sensitive recurrent ovarian cancer

Recruiting
4
60
 
To use Apatinib mesylate tablets,and Paclitaxel and carboplatin ;Only use Paclitaxel and carboplatin
Jiangsu Cancer Hospital; Jiangsu Hengrui pharmaceutical Limited by Share Ltd, Self financing
Oophoroma
 
 
ChiCTR-OPC-17011248: The observation of clinical effect on Apatinib treatment of advanced malignant tumor by the evaluation of Peripheral blood circulating tumor cells

Recruiting
4
20
 
Apatinib
Sir Run Run Shaw Hospital School of Medicine, Zhejiang University; Sir Run Run Shaw Hospital School of mMedicine, Zhejiang University, self-financing
malignant tumor
 
 
ChiCTR1900024189: Clinical Study for Sequential Chemotherapy with Apatinib in Patients with Non-small Cell Lung Cancer

Recruiting
4
60
 
Apatinib Combined with Docetaxel ;Docetaxel
Shanxi Provincial Hospital of Traditional Chinese Medicine; Shanxi Provincial Hospital of Traditional Chinese Medicine, csco hengrui fund
lung cancer
 
 
ChiCTR-IPC-17012721: For the prospective study of apatinib mesylate, single arm, open and exploratory tablets in the treatment of muscle invasive urothelial carcinoma patients

Recruiting
4
20
 
Apatinib + gemcitabine + cisplatin ;gemcitabine + cisplatin
Tangdu Hospital of Air Force Military Medical University; Tangdu Hospital of Air Force Military Medical University, Self financing
Bladder cancer
 
 
ChiCTR1800016882: Esophageal Artery Perfusion Chemotherapy Combined with Apatinib in the Treatment of Advancand Esophageal Carcinoma with Failure of Radiochemotherapy: A Prospective, Exploratory, Open, Single-center, One-arm Clinical Trial

Recruiting
4
60
 
Esophageal cancer infusion chemotherapy combined with apatinib
The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, Self-financing
Esophageal Carcinoma
 
 
ChiCTR-OPC-17013445: An investigation of effect and safety of Apatinib in the treatment of advanced NSCLC

Not yet recruiting
4
100
 
Apatinib
The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University, self-financing
NSCLC
 
 
ChiCTR1800016391: A clinical study of apatinib and cisplatin with concurrent radiotherapy for treatment of cervical cancer

Recruiting
4
218
 
apatinib+cisplatin+radiotherapy ;cisplatin+radiotherapy
The Second Affiliated Hospital of Xi'an Jiaotong University; The Second Affiliated Hospital of Xi'an Jiaotong University, Self financing
cervical cancer
 
 
ChiCTR1800020105: Clinical study for second-line treatment of apatinib mesylate tablets in patients with advanced EGFR wild-type, non-squamous and non-small-cell lung cancer

Completed
4
30
 
Docetaxel 60mg/m2, i.v. repeat three weeks a cycle, 4 - 6 courses; apatinib 250mg, p.o. qd, 28 cycles
Nanjing Military Region General Hospital; Nanjing Military Region General Hospital, self-raised funds
EGFR wild type, scale, non-small cell lung cancer
 
 
ChiCTR1800017323: A phase II study of apatinib combined with with XELOX regimen in the treatment of locally advanced gastric cancer

Recruiting
4
20
 
apatinib combined with with XELOX regimen
The First Affliliated Hospital With Nangjing Medical University(Jiangsu Province Hospital); The First Affliliated Hospital With Nangjing Medical University(Jiangsu Province Hospital), Self financing
gastric cancer
 
 
ChiCTR1800017332: A pilot study for Apatinib Mesylate combined with Gifitinib in First-line treatment of Lung Adenocarcinoma with malignant pleural effusion or pericardial effusion

Recruiting
4
10
 
Apatinib mesylate tablets combined with gefitinib
Jiangsu Subei People's Hospital; Jiangsu Subei People's Hospital, Self-financing
Carcinoma of the lungs
 
 
ChiCTR1800014504: Non-intervention study of apatinib combined with capecitabine versus capecitabine in the treatment of advanced metastatic colorectal cancer

Not yet recruiting
4
138
 
Apatinib + capecitabine ;capecitabine
Affiliated Hospital of North Sichuan Medical College; Affiliated Hospital of North Sichuan Medical College, Self financing
Metastatic colorectal cancer
 
 
ChiCTR1800017837: A single-arm, prospective Clinical Study of apatinib combined with SOX protocol for first-line treatment of advanced gastric cancer

Not yet recruiting
4
30
 
Apatinib combined with SOX
Gansu Province Cancer Hospital; Gansu Province Cancer Hospital, raise independently
not operable, recurrent or metastatic advanced gastric or gastric esophageal junction adenocarcinoma
 
 
ChiCTR1900024399: The Real World Study of Apatinib for Postoperative Adjuvant Therapy of Hepatocellular Carcinoma

Not yet recruiting
4
300
 
Apatinib
Qinzhou First People's Hospital; Qinzhou First People's Hospital, Self-financing
Liver cancer
 
 
ChiCTR-OPN-17011968: Apatinib mesylate tablets combined with docetaxel and nedaplatin in the treatment of advanced ovarian cancer by observational clinical study of postoperative patients

Recruiting
4
40
 
Apatinib + docetaxel plus nedaplatin; docetaxel plus nedaplatin
Tumor Hospital of Shaanxi province; Level of the institution:, Self financing
ovarian cancer
 
 
ChiCTR-IPR-17012667: An prospective, open-label, random and control clinical trail of Apatinib combined with TACE contrast to the simple TACE in the treatment of recurrent hepatocellular carcinoma (HCC)

Recruiting
4
40
 
Apatinib Tablets orally ;TACE
Xinqiao Hospital, Chongqing; Xinqiao Hospital, Chong qing, self financing
Liver cancer
 
 
ChiCTR-OPC-17010708: In the second or higher standard chemotherapy failure in patients with advanced colorectal cancer using mesylate apatinib tablets multicenter, open, single arm and exploratory research

Recruiting
4
54
 
Restricted entry
The first Affiliated Hospita of Nanjing Medical University; The first Affiliated Hospita of Nanjing Medical University, self-raised
Colon cancer
 
 
ChiCTR-OPC-17012676: An prospective, single center, open, stage II clinical trail of Apatinib for treatment of locally advanced or metastatic thyroid undifferentiated thyroid cancer

Recruiting
4
10
 
Apatinib
Zhejiang Cancer Hospital; Zhejiang Cancer Hospital, 1. Hengrui Company, Jiangsu, China; 2. self-raised funds
Undifferentiated thyroid carcinoma
 
 
ChiCTR1800018546: A clinical study for Neoadjuvant Chemotherapy using apatinib plus L-OHP and capecitabine in local advanced gastric cancer

Not yet recruiting
4
48
 
Apatinib combined with XELOX
The First Hospital of Lanzhou University; The First Hospital of Lanzhou University Intervention Department, Self raise independently
Locally advanced gastric cancer
 
 
ChiCTR-OPC-17013262: Clinical study of Apatinib combination with SOX as First line treatment in patients with adenocarcinoma of the Stomach or Gastroesophageal Junction

Recruiting
4
50
 
Apatinib combined with SOX
Shanxi Tumor Hospital; Shanxi Tumor Hospital, No
gastric cancer
 
 
ChiCTR-OPC-17012933: Study of using second-line chemotherapy plus Apatinib in local recurrence or metastatic breast cancer

Recruiting
4
80
 
Apatinib+Second-line chemotherapy
The first Affiliated Hospital of Wenzhou Medical University; The first Affiliated Hospital of Wenzhou Medical University, 1. Hengrui Company, Jiangsu, China; 2. self-raised funds
Breast Cancer
 
 
ChiCTR-OPC-17012473: A prospective, non-intervention real world study of Apatinib in the treatment of advanced lungsquamous carcinoma

Recruiting
4
88
 
apatinib
The Second People's Hospital of Yibin; The Second People's Hospital of Yibin, Self-financing
Lung Cancer
 
 
ChiCTR-OPC-17013162: Phase II multi-center trial of Apatinib combined with EGFR-TKIs therapy in slow progress and T790M of advanced non-small cell lung cancer after treatment with first-generation EGFR-TKIs

Recruiting
4
52
 
Apatinib+EGFR-TKI
Zhejiang Cancer Hospital; Zhejiang Cancer Hospital, 1. Hengrui Company, Jiangsu, China; 2. self-raised funds
non-small cell lung cancer
 
 
ChiCTR-OPC-17013522: An open-label,single-arm trial of HIPEC combined with Apatinib in patients with advanced peritoneal implantation tumor

Suspended
4
30
 
Apatinib+HIPEC
Hangzhou Cancer Hospital; Hangzhou Cancer Hospital, self financing
peritoneal implantation tumor
 
 
ChiCTR-IPR-17011038: Apatinib and radiofrequency ablation treatment with Hepatocellular Carcinoma

Recruiting
4
60
 
Apatinib+ RFA ;RFA
Sir Run Run Shaw Hospital; Sir Run Run Shaw Hospital, self-financing
Hepatocellular Carcinoma
 
 
ChiCTR-OPC-17013602: Clinical study of apatinib combined with oxaliplatin in the treatment of platinum - resistant recurrent ovarian cancer .

Not yet recruiting
4
20
 
Apatinib Tablets orally
Xin qiao Hospital, Chong qing; Xinqiao Hospital, Chong qing, self financing
Ovarian cancer
 
 
ChiCTR-IPR-17010776: A exploratory Study of Apatinib and Gefitinib First-line treatment in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

Not yet recruiting
4
60
 
Gefitinib 250mgpo, qd and Apatinib, 250 mg Po qd ;Gefitinib 250mg po qd
First Affiliated Hospital of Third Military Medical University; First Affiliated Hospital of Third Military Medical University, Hengrui pharmaceutical co., LTD. offers research funding
NSCLC
 
 
ChiCTR1800014964: A prospective ,single arm, open study of Mesylate Apatinib combined with FOLFOX in the treatment of advanced colorectal cancer

Not yet recruiting
4
40
 
Mesylate Apatinib
Affiliated Tumor Hospital of GuangXi Medical University; Level of the institution:, self-raised
colorectal cancer
 
 
ChiCTR1800015196: The prospective and open phase II clinical trial of whole brain radiotherapy combined with anti-angiogenesis therapy for wild-type EGFR non-squamous NSCLC with multiple brain metastases

Not yet recruiting
4
40
 
Apatinib combined with radiotherapy
Yunnan Cancer Hospital; Yunnan Cancer Hospital, Cancer Foundation of China, Fund of Beijing Marathon of Hope
EGFR wild-type non-squamous NSCLC with multiple brain metastases
 
 
ChiCTR1800016448: A clinical study of Apatinib mesylate tablets combined with radiotherapy in the treatment of patients with advanced hepatocellular carcinoma (HCC)

Recruiting
4
60
 
Apatinib mesylate tablets + radiotherapy ;radiotherapy
Tangdu Hospital of Fourth Medical University of Chinese PLA.; Level of the institution:, Self-raised funds
advanced HCC
 
 
ChiCTR1800018500: One-arm, single-center, open-label clinical study of lapatinib mesylate combined with docetaxel in the treatment of lung adenocarcinoma with no driver gene mutation

Not yet recruiting
4
20
 
Apatinib combined with docetaxel
The People's Hospital of Tongliang District, Chongqing; The People's Hospital of Tongliang District.Chongqing City, Jiangsu hengrui pharmaceutical co. LTD
Lung adenocarcinoma without driver gene mutation
 
 
ChiCTR-OPC-17010463: Apatinib and chemotherapy sequential treatment with cervical cancer

Recruiting
4
30
 
Apatinib 250 mg qd, po; standard chemotherapy
Daping Hospital; Daping Hospital, self-financing
cervical cancer
 
 
ChiCTR-RPN-17010462: Apatinib In Combination with chemotherepy in ovarian cancer

Recruiting
4
30
 
Apatinib, 250 mg qd, po; standard chemotherapy
Daping Hospital; Daping Hospital, self-financing
ovarian cancer
 
 
ChiCTR-IPR-17010464: Apatinib and chemotherapy treatment with esophageal cancer

Recruiting
4
40
 
Apatinib, 250 mg Po qd, paclitaxel or docetaxel combined with platinum standard chemotherapy regimens, q21d, 2 to 6 cycles of chemotherapy ;paclitaxel or docetaxel combined with platinum standard chemotherapy regimens,
Daping Hospital; None, self-financing
esophageal cancer
 
 
ChiCTR-IPR-17010456: Apatinib and radiotherapy Compared with zoledronic acid and radiotherapy Treatment in Patients With bone metastases of Malignant tumor

Recruiting
4
60
 
Apatinib, 250 mg po, qd, Local radiotherapy ;zoledronic acid: 4 mg, iv, Every 4 weeks; Local radiotherapy
Da Hospital; Da Hospital, self-financing
cancer
 
 
ChiCTR-OPC-17013964: A Non-randomized, Open-label, Prospective, Multicenter Study of Apatinib Mesylate Tablet as Second-line and Later Therapy in Patients With Extensive Stage Small Cell Lung Cancer

Completed
4
60
 
Restricted entry
Affiliated Hospital of Jiangnan University and Fourth People's Hospital of Wuxi; Affiliated Hospital of Jiangnan University and Fourth People's Hospital of Wuxi, Self financing
Small Cell Lung Cancer
 
 
ChiCTR1800014428: Apatinib mesylate tablets combined with gefitinib in the treatment of non-small cell lung cancer with gefitinib T790M mutation, single center, open, single arm clinical study

Recruiting
4
30
 
apatinib
Xijing Hospital; Xijing Hospital, Self financing
lung cancer
 
 
ChiCTR1800014313: A real world study of sequential study of SBRT sequential therapy with apatinib mesylate in the treatment of advanced liver cancer

Not yet recruiting
4
30
 
SBRT followed by apatinib ;apatinib
Sichuan Provincial People's Hospital; Sichuan Provincial People’s Hospital, Jiangsu Hengrui Medicine Co., Ltd funded
liver cancer
 
 
ChiCTR1800017789: A real world major data study for Apatinib in the treatment of advanced gastric cancer

Not yet recruiting
4
1000
 
Apatinib
Zhejiang Provincial Hospital of TCM, Zhejiang Cancer Hospital; Zhejiang Provincial Hospital of TCM, self-financing
advanced gastric cancer
 
 
ChiCTR1900021506: Therapeutic effect of apatinib monotherapy on recurrence and persistent cervical squamous cell carcinoma due to failure of chemoradiotherapy or other targeted therapy and correlation research between the efficacy of apatinib and the angiogenesis immune response subtype gene

Not yet recruiting
4
40
 
Apatinib monotherapy
Chongqing Cancer Hospital; Chongqing Cancer Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd.
Cervical squamous cell carcinoma
 
 
ChiCTR1900020825: One-arm, open clinical study of apatinib mesylate combined with EGFR-TKI in the treatment of advanced non-squamous cell lung cancer patients with EGFR gene mutation

Not yet recruiting
4
120
 
apatinib combined with EGFR-TKI
Affiliated Hospital of Inner Mongolia Medical University; Affiliated Hospital of Inner Mongolia Medical University, Self financing
lung cancer
 
 
ChiCTR1800015057: Third-line therapy with apatinib in metastatic colorectal cancer: individualized dose adjustment based on plasma concentration and adverse reactions

Recruiting
4
36
 
apatinib
West China Hospital, Sichuan University; West China Hospital, Sichuan University, Self financing
Metastatic colorectal cancer
 
 
ChiCTR1800015920: Efficacy and safety of apatinib combined with pemetrexed plus platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer

Completed
4
40
 
apatinib 250mg Qd combined with chemotherapy ;apatinib 500mg Qd combined with chemotherapy
National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Foundation of China, Terry Fox Run, Marathon of Hope
Non-squamous non-small cell lung cancer
 
 
ChiCTR1800015764: Single arm, open, prospective study low dose of Apatinib in the treatment of primary and recurrent high grade gliomas

Recruiting
4
30
 
apatinib + Temozolomide + radiotherapy
Gansu Province Cancer Hospital; Gansu Province Cancer Hospital, raise independently
primary and recurrent high grade gliomas
 
 
ChiCTR-OPC-17011039: Apatinib and radiofrequency ablation treatment with lung cancer

Recruiting
4
30
 
Apatinib+ RFA
Sir Run Run Shaw Hospital; Sir Run Run Shaw Hospital, self-financing
lung cancer
 
 
ChiCTR1800016501: Apatinib combined with pemetrexed plus cisplatin as the first-line treatment of patients with negative diver gene advanced non-squamous non-small cell lung cancer: a single - center and single - arm clinical study

Recruiting
4
20
 
apatinib
Affiliated Hospital of Shandong Academy of Medical Sciences; Affiliated Hospital of Shandong Academy of Medical Sciences, self financing
negative diver gene advanced non-squamous non-small cell lung cancer
 
 
ChiCTR1800017225: Clinical study of apatinib mesylate combined with paclitaxel in second-line and second-line maintenance of advanced gastric cancer

Recruiting
4
60
 
apatinib mesylate combined with paclitaxel
Jiangxi Tumor Hospital; Jiangxi Tumor Hospital, Jiangsu hengrui pharmaceutical co. LTD
gastric cancer
 
 
ChiCTR1900020699: Randomized controlled prospective trial for apatinib mesylate combined with TACE in the treatment of advanced hepatocellular carcinoma

Recruiting
4
120
 
TACE+Oral administration of apatinib at 500mg/ day ;Only TACE
The First Affiliated Hospital of Nanchang University; The First Affiliated Hospital of Nanchang University, At his own expense
liver cancer
 
 
ChiCTR-OPN-16008694: Clinical study of Apatinib Mesylate Tablets unite Docetaxel in the Second-line treatment of EGFR Wild-type Advanced Non-Squamous Non-Small Cell Lung Cancer

Not yet recruiting
4
55
 
Apatinib and docetaxel
Huizhou People's Hospital; Huizhou People's Hospital, self-financing
EGFR Wild-type Advanced Non-Squamous Non-Small Cell Lung Cancer
 
 
ChiCTR1800017424: Mesylate tablets of apatinib as first-line treatment of metastatic soft tissue sarcoma, randomized, crossover, multi center clinical study

Recruiting
4
80
 
IFO+EPI regimen ;Pan apatinib scheme
General Hospital of Shenyang Military Area Command; General Hospital of Shenyang Military Area Command, Self-raising
metastatic soft tissue sarcoma
 
 
ChiCTR1800016529: A prospective, open label, randomized, controlled trial for evaluation of the safety and efficacy of Apatinib mesylate tablets combined with docetaxel in the treatment of metastatic breast cancer

Recruiting
4
130
 
Apatinib Mesylate Tablets versus Docetaxel combined with Docetaxel
Breast center of Jiangxi Tumor Hospital; Level of the institution:, Self financing
breast cancer
 
 
ChiCTR1800018642: An exploration of Apatinib Plus IP solution as 2nd Line Treatment in Patients With Small Cell Lung Cancer

Recruiting
4
30
 
apatinib mesylate combined with IP chemotherapy
Affiliated Cancer Hospital of Harbin Medical University; Affiliated Cancer Hospital of Harbin Medical University, By oneself
Non-small Cell Lung Cancer
 
 
ChiCTR1800017537: One-arm, single-center, open-label clinical study of concurrent chemoradiotherapy combined with adjuvant chemotherapy and antiangiogenic therapy for advanced malignant tumors

Not yet recruiting
4
30
 
Apatinib monotherapy or apatinib combined with other drugs
Chongqing Cancer Hospital; ChongQing Cancer Hospital, Jiangsu hengrui pharmaceutical co. LTD
advanced malignant solid tumors
 
 
ChiCTR1800017333: Therapeutic effect of transcatheter arterial chemoembolization(TACE) combined with anti-angiogenesis therapy on patients with liver cancer

Not yet recruiting
4
20
 
TACE+Apatinib
The Second Affiliated Hospital of Chongqing Medical University; The Second Affiliated Hospital of Chongqing Medical University, Jiangsu Hengrui Pharmaceutical co. LTD
Hepatocellular carcinoma
 
 
ChiCTR1800017375: Observational clinical study of apatinib for advanced malignant solid tumors

Recruiting
4
30
 
Apatinib monotherapy or apatinib combined with other drugs
The First Hospital Affiliated to AMU/Southwest Hospital; The First Hospital Affiliated to AMU/Southwest Hospital, Jiangsu hengrui pharmaceutical co. LTD.
advanced malignant solid tumors
 
 
ChiCTR1800017511: Study on the maintenance of apatinib and the administration of apatinib in patients with primary liver cancer after TACE treatment

Recruiting
4
40
 
Apatinib monotherapy for maintenance after TACE treatment
Chongqing Cancer Hospital; Chongqing Cancer Hospital, Jiangsu hengrui pharmaceutical co. LTD
Hepatocellular carcinoma that cannot be resected or relapses after resection
 
 
ChiCTR1800014477: Mesylate apatinib as monotherapy or in combination with capecitabine in the treatment of advanced breast cancer multicenter, open, single arm clinical study

Not yet recruiting
4
96
 
apatinib or apatinib plus capecitabine
Sui'ning Central Hospital; Sui'ning Central Hospital, Self financing
advanced breast cancer
 
 
ChiCTR1800017494: A prospective, open-label, one-arm clinical study of pemetrexed in combination with platinum-based regimens in patients with advanced non-squamous non-small cell lung cancer treated with apatinib after 4-6 cycles of chemotherapy

Not yet recruiting
4
20
 
Apatinib monotherapy for maintenance treatment
Xinqiao Hospital, Army Medical University; XinQiao Hospital, Amy Medical University, Jiangsu hengrui pharmaceutical co. LTD
Non-scale non-small cell lung cancer
 
 
ChiCTR1800017503: Clinical study for effect and safety, as well as prognostic factors analysis of apapitatin mesylate combined with TACE in the treatment of patients with advanced hepatocellular carcinoma

Not yet recruiting
4
40
 
Apatinib monotherapy for maintenance treatment after TACE treatment
Daping Hospital, Army Medical University; DaPing Hospital, Army Medical University, Jiangsu hengrui pharmaceutical co. LTD
Advanced hepatocellular carcinoma
 
 
ChiCTR1900027247: One-arm clinical study for camrelizumab, apatinib mesylate and TACE in the treatment of advanced hepatocellular carcinoma

Recruiting
4
20
 
camrelizumab, apatinib mesylate and TACE
The First Affiliated Hospital of Suzhou University; The First Affiliated Hospital of Suzhou University, Self financing
Liver cancer
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AiTan (rivoceranib) / HLB Bio Group
ChiCTR-OPN-16009458: A clinical research of Apatinib unite chemotherapy in second-line treatment of advanced lung cancer, gastric cancer and colorectal cancer

Recruiting
4
90
 
combination of apatinib based on the second-line chemotherapy
Suzhou City Hospital; Suzhou City Hospital, self-financing
cancer
 
 
ChiCTR-OPN-16009457: A exploratory controlled clinical study of Apatinib combined TACE in treating advanced hepatocellular carcinoma

Recruiting
4
100
 
Apatinib Mesylate Tablets
the First affiliated Hospital of SooChow University; the First affiliated Hospital of SooChow University, self-financing
cancer
 
 
ChiCTR-OPC-17011020: A clinical research of Apatinib in the treatment of advanced refractory non-small cell lung cancer

Recruiting
4
30
 
Apatinib
101th Hospital of PLA; Level of the institution:, Self-raised funds
NSCLC
 
 
ChiCTR1800015701: A Real-world Study of Apatinib in the treatment for Inoperable or advanced gastric cancer in Shandong

Recruiting
4
1000
 
apatinib
Shandong Cancer Hospital; Jiangsu Hengrui Medicine Co., Ltd., self-financing
Inoperable or advanced gastric cancer
 
 
ChiCTR2000040387: A real-world study of apatinib combined with TACE in patients with advanced liver cancer

Recruiting
4
300
 
apatinib
The First Affiliated Hospital of University of Science and Technology of China; The First Affiliated Hospital of University of Science and Technology of China, self-financing
Intermediate to advanced hepatocellular carcinoma
 
 
ChiCTR2100041973: A prospective, open, single-arm, single-center phase II clinical study of carrelizumab combined with apatinib and tigio capsules in the second-line treatment of patients with metastatic cholangiocarcinoma

Recruiting
4
30
 
Patients with metastatic biliary tract cancer (including gallbladder cancer and cholangiocarcinoma) who have undergone first-line treatment
The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, Self-funded
Cholangiocarcinoma
 
 
ChiCTR2100044694: The prognostic value of PD-L1 in the treatment of advanced hepatocellular carcinoma with combination of apatinib and karelizumab

Recruiting
4
30
 
They were treated with apatinib and karelizumab combined system, without TACE and other local treatment ;The patients with HCC were treated with apatinib and karelizumab combined with TACE
Shandong Provincial Hospital; Shandong Provincial Hospital, China Health Promotion Foundation
Advanced hepatocellular carcinoma
 
 
ChiCTR-OPN-15006601: A prospectiv, multi-center, non-intervention study of Apatinib in the treatment of advanced gastric cancer

Recruiting
4
230
 
apatinib
Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, self-financing
advanced gastric cancer
 
 
ChiCTR-OPN-15007034: A prospective, multi-center study of Apatinib in the treatment of advanced cancer

Recruiting
4
100
 
none
The Second Affiliated Hospital of Soochow University; the Second Affiliated Hospital of Soochow University, self-financing
cancer
 
 
ChiCTR-IPR-15006993: Apatinib as Maintenance Therapy After First-line Chemotherapy (DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer

Not yet recruiting
4
48
 
Apatinib Mesylate Tablets 500 mg qd p.o. ;Best Support Care
Fourth Hospital, Hebei Medical University; Hebei Medical University affiliated Fourth Hospital, self-raise
Gastric Cancer
 
 
ChiCTR-OPC-16010108: The clinical study of Apatinib mesylate combined with Temozolomide in treating patients with recurrent high-grade glioma

Recruiting
4
40
 
Apatinib Mesylate Tablets
the First affiliated Hospital of SooChow University; the First affiliated Hospital of SooChow University, self-financing
cancer
 
 
ChiCTR-OPN-15007443: A prospectiv, single-arm study of Apatinib unite docetaxel in the treatment of advanced squamous cell carcinoma of the lung

Recruiting
4
60
 
Apatinib unite docetaxel
the second people's hospital of lianyungang; The Second People's Hospital of Lianyungang, self-financing
advanced squamous cell carcinoma of the lung
 
 
ChiCTR-OPC-16008295: A observational clinical study of Apatinib combined chemotherapy in the treatment of gastric cancer with AFP positive

Not yet recruiting
4
16
 
combined chemotherapy
Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, self-financing
advanced gastric cancer
 
 
ChiCTR-OPC-16008296: A clinical study of Apatinib combined chemotherapy in the treatment of advanced gastric cancer with malignant peritoneal effusion

Not yet recruiting
4
30
 
combined chemotherapy
Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, self-financing
advanced gastric cancer
 
 
ChiCTR-IPR-16008335: A clinical study of postoperative adjuvant chemotherapy in the treatment of gastric carcinoma unite Apatinib

Not yet recruiting
4
60
 
combined chemotherapy
The People's Liberation Army 101 Hospital; The People's Liberation Army 101 Hospital, self-financing
gastric cancer
 
 
ChiCTR-OPC-16009048: Clinical study of Apatinib Mesylate Tablets in the Second-line treatment of Advanced Squamous Cell Lung Cancer

Recruiting
4
30
 
combined S-1
Anhui Chest Hospital; Anhui Chest Hospital, self-financing
Squamous Cell Lung Cancer
 
 
ChiCTR-OPC-16007953: Clinical study of apatinib mesylate tablets in the treatment of refractory soft tissue sarcoma

Not yet recruiting
4
30
 
Medical and nursing education for patients with soft tissue sarcoma
Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, Henry csco- Cancer Research Fund
Refractory soft tissue sarcoma
 
 
ChiCTR-IPR-15006994: Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells

Not yet recruiting
4
48
 
Apatinib Mesylate Tablets 500 mg qd p.o. ;Best Support Care
Fourth Hospital, Hebei Medical University; Hebei Medical University affiliated Fourth Hospital, self-raise
Gastric Cancer
 
 
ChiCTR-IPR-17010361: First-line randomized, open, controlled clinical trial of EP regimen with sequential apatinib in patients with extensive stage small cell lung cancer

Not yet recruiting
4
120
 
EP, 80mg/ m D1 cisplatin, etoposide 100mg/ square meters, D1-3, apatinib mesylate tablets: 500 or 750 mg QD Po, D4 to the next cycle of twenty-first days, 4 weeks for 1 cycles, 2 cycles of evaluation time, 6 cycle withdrawal. ;EP, 80mg/ m D1 cisplatin, etoposide 100mg/ square meters, D1-3, cycle of twenty-first days, 4 weeks for 1 cycles, 2 cycles of evaluation time, 6 cycle withdrawal.
The North Hospital of the Affiliated Hospital of Qiingdao University hospital; The North Hospital of the Affiliated Hospital of Qiingdao University hospital, CSCO Fund / Jiangsu Hengrui Medicine Co. Ltd.
extensive stage small cell lung cancer
 
 
ChiCTR-OPC-16009849: A study to determine the curative effect and mechanism of Apatinib combined with chemotherapy for SD patients with advanced malignant solid tumor

Recruiting
4
100
 
Apatinib Mesylate Tablets
the First affiliated Hospital of SooChow University; the First affiliated Hospital of SooChow University, self-financing
cancer
 
 
ChiCTR-OPC-17013834: Clinical study of Apatinib combined with docetaxel as second-line treatment in advanced gastric cancer

Recruiting
4
20
 
Apatinib combined with Docetaxel
Shanxi Tumor Hospital; Shanxi Tumor Hospital, Chinese Anti-Cancer Association- HengRui pharmaceutical innovative medicine clinical research fund
gastric cancer
 
 
ChiCTR-OPC-17011019: An opening, single arm study of Apatinib in the treatment of advanced hepatocellular carcinoma

Recruiting
4
60
 
Apatinib
Huai'an First People's Hospital, Nanjing Medical University; Huai'an First People's Hospital, Nanjing Medical University, Jiangsu Hengrui Medicine Co., Ltd.
hepatocellular carcinoma
 
 
ChiCTR-OPC-17011376: The clinical research of Apatinib for the treatment of advanced non-small cell lung cancer

Recruiting
4
30
 
Apatinib
the First affiliated Hospital of SooChow University; the First affiliated Hospital of SooChow University, self-financing
cancer
 
 
ChiCTR-OPC-17011378: The clinical observational study of Apatinib 425mg Joint docetaxel for the second-line treatment of advanced lung squamous carcinoma

Recruiting
4
30
 
Apatinib +docetaxel
the First affiliated Hospital of SooChow University; the First affiliated Hospital of SooChow University, self-financing
cancer
 
 
ChiCTR-OPC-16008637: A Study of Second-line Treatment With Apatinib and S-1 in Advanced Hepatocellular Carcinoma Patients

Recruiting
4
120
 
Apatinib 500mg/day ;Apatinib 750mg/day ;S-1
the First Affiliated Hospital of Zhengzhou University; the First Affiliated Hospital of Zhengzhou University, CSCO- Henry Cancer Research Fund
Advanced Hepatocellular
 
 
ChiCTR-OPC-16009894: Exploratory clinical study of apatinib mesylate tablets in the treatment of EGFR negative patients with non squamous non-small cell lung cancer.

Recruiting
4
40
 
Apatinib + cisplatin + docetaxel ;cisplatin + docetaxel
The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University, raise independently
lung cancer
 
 
ChiCTR-OPC-17011822: A clinical study of Apatinib combined TACE in treating intermediate and advanced hepatocellular carcinoma

Recruiting
4
100
 
Apatinib+TACE
the First affiliated Hospital of SooChow University; the First affiliated Hospital of SooChow University, self-financing
cancer
 
 
ChiCTR-OPC-17010714: Apatinib Mesylate Tablets of joint mFOLFOX6 neoadjuant chemotherapy in locally advanced colorectal cancer clinical research

Recruiting
4
60
 
Apatinib Mesylate Tablets of joint mFOLFOX6 neoadjuant chemotherapy
Tianjin people's hospital; Tianjin people's hospital, Jiang Su Heng Rui medicine. co.LTD
Colorectal cancer
 
 
ChiCTR1800015202: Clinical study of Apatinib combined with chemotherapy or single Drug for second-line treatment failure in advanced ovarian cancer

Not yet recruiting
4
30
 
Apatinib combined with conventional chemotherapy regimen
Yibin second people's Hospital; Yibin second people's Hospital, Self financing
ovarian cancer
 
 
ChiCTR-OIC-16008894: Taxanes combined with Apatinib mesylate in the treatment for patients with advanced breast cancer: an open-label, single-arm, single-center clinical research

Recruiting
4
30
 
Apatinib 500mg/day
The First Hospital of Lanzhou Uiversity; The First Hospital of Lanzhou University, self-financing
advanced breast cancer
 
 
ChiCTR-OPC-17011722: An open and one-armed exploration of Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-small Cell Lung Cancer

Recruiting
4
80
 
Apatinib+Docetaxel
The First Affiliated Hospital Of Nanchang University; The First Affiliated Hospital Of Nanchang University, self-financing
cancer
 
 
ChiCTR-OPC-16009725: Apatinib as Adjuvant Treatment in the Recurrence of Hepatocellular Carcinoma

Recruiting
4
40
 
Apatinib 250mg/Day
Nanjing Drum Tower Hospital; Nanjing Drum Tower Hospital, self-financing
Hepatocellular carcinoma
 
 
ChiCTR-OPN-17013220: An open-label, single-arm, prospective study of TACE combined with apatinib for unresectable liver metastases from colorectal cancer

Recruiting
4
20
 
TACE combined with apatinib
Yueyang Hospital of integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Mesdicne; Yueyang Hospital of integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Mesdicne, self-raised
colorectal liver metastases
 
 
ChiCTR-OPN-17013304: Clinical study of first-line therapy with Apatinib Mesylate in combination with chemotherapy for EGFR-negative advanced non-small cell lung cancer

Recruiting
4
60
 
Apatinib + Docetaxel + Platinum; Docetaxel + Platinum
2nd People's Hospital of Fuyang City; 2nd People's Hospital of Fuyang City, self-financing
NSCLC
 
 
ChiCTR1800020145: Open, single-arm, exploratory study for apatinib mesylate in the treatment of recurrent glioma

Completed
4
32
 
Patients were treated with temozolomide combined with apatinib
Sanbo Brain Hospital, Capital Medical University; Sanbo Brain Hospital, Capital Medical Universit, Jiangsu hengrui pharmaceutical co., LTD
glioma
 
 
ChiCTR-OPC-17010758: Mesylate apatinib combined with chemotherapy in the treatment of clinical study of osteosarcoma recurrence and metastasis

Recruiting
4
40
 
Apatinib or apatinib + chemotherapy
Xijing Hospital affiliated to The Fourth Military Medical University; Xijing Hospital affiliated to The Fourth Military Medical University, 经费自筹 Self financing
osteosarcoma
 
 
ChiCTR-OPC-17012186: An prospective, single-arm, multi-center clinical trial of Apatinib combined with capecitabine in the treatment of advanced ovarian cancer

Recruiting
4
30
 
combined Capecitabine
The Second People's Hospital of Hefei; The Second People's Hospital of Hefei, self-financing
Ovarian cancer
 
 
ChiCTR-OPC-17010671: Clinical study of combined use of apatinib in patients with locally advanced cervical cancer during concurrent radiotherapy and chemotherapy

Not yet recruiting
4
30
 
Apatinib + cisplatin + radiotherapy
Qinghai Red Cross Hospital; Qinghai Red Cross Hospital, Self financing
locally advanced cervical carcinoma
 
 
ChiCTR-OPN-17011652: A clinical study of recurrent ovarian ovarian cancer in the treatment of platinum resistance in apatinib tablet

Not yet recruiting
4
280
 
Apatinib + chemotherapy ;Pure chemotherapy
Xijing Hospital affiliated to The Fourth Military Medical University; Xijing Hospital affiliated to The Fourth Military Medical University, Self financing
Late-stage platinum resistant ovarian cancer
 
 
ChiCTR-OPC-17010572: Clinical study of adenocarcinoma with apatinib mesylate tablets combined with chemotherapy as second-line treatment of advanced gastric cancer or gastric esophagus

Not yet recruiting
4
100
 
limit into the grop and the ruled out
Yangzhong People's Hospital; Yangzhong People's Hospital, self-raised
gastric cancer
 
 
ChiCTR1800015308: A multi-center single arm study of FOLFIRI combined with Apatinib on the treatment of non resectable metastatic colorectal cancer

Recruiting
4
40
 
FOLFIRI combined with apatinib
Shanxi Tumor Hospital; Shanxi Tumor Hospital, Chinese Anti-Cancer Association- HengRui pharmaceutical innovative medicine clinical research fund
advanced colorectal cancer
 
 
ChiCTR1800015494: Clinical study of apatinib mesylate tablets combined with chemotherapy in the treatment of platinum sensitive recurrent ovarian cancer

Recruiting
4
60
 
To use Apatinib mesylate tablets,and Paclitaxel and carboplatin ;Only use Paclitaxel and carboplatin
Jiangsu Cancer Hospital; Jiangsu Hengrui pharmaceutical Limited by Share Ltd, Self financing
Oophoroma
 
 
ChiCTR-OPC-17011248: The observation of clinical effect on Apatinib treatment of advanced malignant tumor by the evaluation of Peripheral blood circulating tumor cells

Recruiting
4
20
 
Apatinib
Sir Run Run Shaw Hospital School of Medicine, Zhejiang University; Sir Run Run Shaw Hospital School of mMedicine, Zhejiang University, self-financing
malignant tumor
 
 
ChiCTR1900024189: Clinical Study for Sequential Chemotherapy with Apatinib in Patients with Non-small Cell Lung Cancer

Recruiting
4
60
 
Apatinib Combined with Docetaxel ;Docetaxel
Shanxi Provincial Hospital of Traditional Chinese Medicine; Shanxi Provincial Hospital of Traditional Chinese Medicine, csco hengrui fund
lung cancer
 
 
ChiCTR-IPC-17012721: For the prospective study of apatinib mesylate, single arm, open and exploratory tablets in the treatment of muscle invasive urothelial carcinoma patients

Recruiting
4
20
 
Apatinib + gemcitabine + cisplatin ;gemcitabine + cisplatin
Tangdu Hospital of Air Force Military Medical University; Tangdu Hospital of Air Force Military Medical University, Self financing
Bladder cancer
 
 
ChiCTR1800016882: Esophageal Artery Perfusion Chemotherapy Combined with Apatinib in the Treatment of Advancand Esophageal Carcinoma with Failure of Radiochemotherapy: A Prospective, Exploratory, Open, Single-center, One-arm Clinical Trial

Recruiting
4
60
 
Esophageal cancer infusion chemotherapy combined with apatinib
The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, Self-financing
Esophageal Carcinoma
 
 
ChiCTR-OPC-17013445: An investigation of effect and safety of Apatinib in the treatment of advanced NSCLC

Not yet recruiting
4
100
 
Apatinib
The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University, self-financing
NSCLC
 
 
ChiCTR1800016391: A clinical study of apatinib and cisplatin with concurrent radiotherapy for treatment of cervical cancer

Recruiting
4
218
 
apatinib+cisplatin+radiotherapy ;cisplatin+radiotherapy
The Second Affiliated Hospital of Xi'an Jiaotong University; The Second Affiliated Hospital of Xi'an Jiaotong University, Self financing
cervical cancer
 
 
ChiCTR1800020105: Clinical study for second-line treatment of apatinib mesylate tablets in patients with advanced EGFR wild-type, non-squamous and non-small-cell lung cancer

Completed
4
30
 
Docetaxel 60mg/m2, i.v. repeat three weeks a cycle, 4 - 6 courses; apatinib 250mg, p.o. qd, 28 cycles
Nanjing Military Region General Hospital; Nanjing Military Region General Hospital, self-raised funds
EGFR wild type, scale, non-small cell lung cancer
 
 
ChiCTR1800017323: A phase II study of apatinib combined with with XELOX regimen in the treatment of locally advanced gastric cancer

Recruiting
4
20
 
apatinib combined with with XELOX regimen
The First Affliliated Hospital With Nangjing Medical University(Jiangsu Province Hospital); The First Affliliated Hospital With Nangjing Medical University(Jiangsu Province Hospital), Self financing
gastric cancer
 
 
ChiCTR1800017332: A pilot study for Apatinib Mesylate combined with Gifitinib in First-line treatment of Lung Adenocarcinoma with malignant pleural effusion or pericardial effusion

Recruiting
4
10
 
Apatinib mesylate tablets combined with gefitinib
Jiangsu Subei People's Hospital; Jiangsu Subei People's Hospital, Self-financing
Carcinoma of the lungs
 
 
ChiCTR1800014504: Non-intervention study of apatinib combined with capecitabine versus capecitabine in the treatment of advanced metastatic colorectal cancer

Not yet recruiting
4
138
 
Apatinib + capecitabine ;capecitabine
Affiliated Hospital of North Sichuan Medical College; Affiliated Hospital of North Sichuan Medical College, Self financing
Metastatic colorectal cancer
 
 
ChiCTR1800017837: A single-arm, prospective Clinical Study of apatinib combined with SOX protocol for first-line treatment of advanced gastric cancer

Not yet recruiting
4
30
 
Apatinib combined with SOX
Gansu Province Cancer Hospital; Gansu Province Cancer Hospital, raise independently
not operable, recurrent or metastatic advanced gastric or gastric esophageal junction adenocarcinoma
 
 
ChiCTR1900024399: The Real World Study of Apatinib for Postoperative Adjuvant Therapy of Hepatocellular Carcinoma

Not yet recruiting
4
300
 
Apatinib
Qinzhou First People's Hospital; Qinzhou First People's Hospital, Self-financing
Liver cancer
 
 
ChiCTR-OPN-17011968: Apatinib mesylate tablets combined with docetaxel and nedaplatin in the treatment of advanced ovarian cancer by observational clinical study of postoperative patients

Recruiting
4
40
 
Apatinib + docetaxel plus nedaplatin; docetaxel plus nedaplatin
Tumor Hospital of Shaanxi province; Level of the institution:, Self financing
ovarian cancer
 
 
ChiCTR-IPR-17012667: An prospective, open-label, random and control clinical trail of Apatinib combined with TACE contrast to the simple TACE in the treatment of recurrent hepatocellular carcinoma (HCC)

Recruiting
4
40
 
Apatinib Tablets orally ;TACE
Xinqiao Hospital, Chongqing; Xinqiao Hospital, Chong qing, self financing
Liver cancer
 
 
ChiCTR-OPC-17010708: In the second or higher standard chemotherapy failure in patients with advanced colorectal cancer using mesylate apatinib tablets multicenter, open, single arm and exploratory research

Recruiting
4
54
 
Restricted entry
The first Affiliated Hospita of Nanjing Medical University; The first Affiliated Hospita of Nanjing Medical University, self-raised
Colon cancer
 
 
ChiCTR-OPC-17012676: An prospective, single center, open, stage II clinical trail of Apatinib for treatment of locally advanced or metastatic thyroid undifferentiated thyroid cancer

Recruiting
4
10
 
Apatinib
Zhejiang Cancer Hospital; Zhejiang Cancer Hospital, 1. Hengrui Company, Jiangsu, China; 2. self-raised funds
Undifferentiated thyroid carcinoma
 
 
ChiCTR1800018546: A clinical study for Neoadjuvant Chemotherapy using apatinib plus L-OHP and capecitabine in local advanced gastric cancer

Not yet recruiting
4
48
 
Apatinib combined with XELOX
The First Hospital of Lanzhou University; The First Hospital of Lanzhou University Intervention Department, Self raise independently
Locally advanced gastric cancer
 
 
ChiCTR-OPC-17013262: Clinical study of Apatinib combination with SOX as First line treatment in patients with adenocarcinoma of the Stomach or Gastroesophageal Junction

Recruiting
4
50
 
Apatinib combined with SOX
Shanxi Tumor Hospital; Shanxi Tumor Hospital, No
gastric cancer
 
 
ChiCTR-OPC-17012933: Study of using second-line chemotherapy plus Apatinib in local recurrence or metastatic breast cancer

Recruiting
4
80
 
Apatinib+Second-line chemotherapy
The first Affiliated Hospital of Wenzhou Medical University; The first Affiliated Hospital of Wenzhou Medical University, 1. Hengrui Company, Jiangsu, China; 2. self-raised funds
Breast Cancer
 
 
ChiCTR-OPC-17012473: A prospective, non-intervention real world study of Apatinib in the treatment of advanced lungsquamous carcinoma

Recruiting
4
88
 
apatinib
The Second People's Hospital of Yibin; The Second People's Hospital of Yibin, Self-financing
Lung Cancer
 
 
ChiCTR-OPC-17013162: Phase II multi-center trial of Apatinib combined with EGFR-TKIs therapy in slow progress and T790M of advanced non-small cell lung cancer after treatment with first-generation EGFR-TKIs

Recruiting
4
52
 
Apatinib+EGFR-TKI
Zhejiang Cancer Hospital; Zhejiang Cancer Hospital, 1. Hengrui Company, Jiangsu, China; 2. self-raised funds
non-small cell lung cancer
 
 
ChiCTR-OPC-17013522: An open-label,single-arm trial of HIPEC combined with Apatinib in patients with advanced peritoneal implantation tumor

Suspended
4
30
 
Apatinib+HIPEC
Hangzhou Cancer Hospital; Hangzhou Cancer Hospital, self financing
peritoneal implantation tumor
 
 
ChiCTR-IPR-17011038: Apatinib and radiofrequency ablation treatment with Hepatocellular Carcinoma

Recruiting
4
60
 
Apatinib+ RFA ;RFA
Sir Run Run Shaw Hospital; Sir Run Run Shaw Hospital, self-financing
Hepatocellular Carcinoma
 
 
ChiCTR-OPC-17013602: Clinical study of apatinib combined with oxaliplatin in the treatment of platinum - resistant recurrent ovarian cancer .

Not yet recruiting
4
20
 
Apatinib Tablets orally
Xin qiao Hospital, Chong qing; Xinqiao Hospital, Chong qing, self financing
Ovarian cancer
 
 
ChiCTR-IPR-17010776: A exploratory Study of Apatinib and Gefitinib First-line treatment in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

Not yet recruiting
4
60
 
Gefitinib 250mgpo, qd and Apatinib, 250 mg Po qd ;Gefitinib 250mg po qd
First Affiliated Hospital of Third Military Medical University; First Affiliated Hospital of Third Military Medical University, Hengrui pharmaceutical co., LTD. offers research funding
NSCLC
 
 
ChiCTR1800014964: A prospective ,single arm, open study of Mesylate Apatinib combined with FOLFOX in the treatment of advanced colorectal cancer

Not yet recruiting
4
40
 
Mesylate Apatinib
Affiliated Tumor Hospital of GuangXi Medical University; Level of the institution:, self-raised
colorectal cancer
 
 
ChiCTR1800015196: The prospective and open phase II clinical trial of whole brain radiotherapy combined with anti-angiogenesis therapy for wild-type EGFR non-squamous NSCLC with multiple brain metastases

Not yet recruiting
4
40
 
Apatinib combined with radiotherapy
Yunnan Cancer Hospital; Yunnan Cancer Hospital, Cancer Foundation of China, Fund of Beijing Marathon of Hope
EGFR wild-type non-squamous NSCLC with multiple brain metastases
 
 
ChiCTR1800016448: A clinical study of Apatinib mesylate tablets combined with radiotherapy in the treatment of patients with advanced hepatocellular carcinoma (HCC)

Recruiting
4
60
 
Apatinib mesylate tablets + radiotherapy ;radiotherapy
Tangdu Hospital of Fourth Medical University of Chinese PLA.; Level of the institution:, Self-raised funds
advanced HCC
 
 
ChiCTR1800018500: One-arm, single-center, open-label clinical study of lapatinib mesylate combined with docetaxel in the treatment of lung adenocarcinoma with no driver gene mutation

Not yet recruiting
4
20
 
Apatinib combined with docetaxel
The People's Hospital of Tongliang District, Chongqing; The People's Hospital of Tongliang District.Chongqing City, Jiangsu hengrui pharmaceutical co. LTD
Lung adenocarcinoma without driver gene mutation
 
 
ChiCTR-OPC-17010463: Apatinib and chemotherapy sequential treatment with cervical cancer

Recruiting
4
30
 
Apatinib 250 mg qd, po; standard chemotherapy
Daping Hospital; Daping Hospital, self-financing
cervical cancer
 
 
ChiCTR-RPN-17010462: Apatinib In Combination with chemotherepy in ovarian cancer

Recruiting
4
30
 
Apatinib, 250 mg qd, po; standard chemotherapy
Daping Hospital; Daping Hospital, self-financing
ovarian cancer
 
 
ChiCTR-IPR-17010464: Apatinib and chemotherapy treatment with esophageal cancer

Recruiting
4
40
 
Apatinib, 250 mg Po qd, paclitaxel or docetaxel combined with platinum standard chemotherapy regimens, q21d, 2 to 6 cycles of chemotherapy ;paclitaxel or docetaxel combined with platinum standard chemotherapy regimens,
Daping Hospital; None, self-financing
esophageal cancer
 
 
ChiCTR-IPR-17010456: Apatinib and radiotherapy Compared with zoledronic acid and radiotherapy Treatment in Patients With bone metastases of Malignant tumor

Recruiting
4
60
 
Apatinib, 250 mg po, qd, Local radiotherapy ;zoledronic acid: 4 mg, iv, Every 4 weeks; Local radiotherapy
Da Hospital; Da Hospital, self-financing
cancer
 
 
ChiCTR-OPC-17013964: A Non-randomized, Open-label, Prospective, Multicenter Study of Apatinib Mesylate Tablet as Second-line and Later Therapy in Patients With Extensive Stage Small Cell Lung Cancer

Completed
4
60
 
Restricted entry
Affiliated Hospital of Jiangnan University and Fourth People's Hospital of Wuxi; Affiliated Hospital of Jiangnan University and Fourth People's Hospital of Wuxi, Self financing
Small Cell Lung Cancer
 
 
ChiCTR1800014428: Apatinib mesylate tablets combined with gefitinib in the treatment of non-small cell lung cancer with gefitinib T790M mutation, single center, open, single arm clinical study

Recruiting
4
30
 
apatinib
Xijing Hospital; Xijing Hospital, Self financing
lung cancer
 
 
ChiCTR1800014313: A real world study of sequential study of SBRT sequential therapy with apatinib mesylate in the treatment of advanced liver cancer

Not yet recruiting
4
30
 
SBRT followed by apatinib ;apatinib
Sichuan Provincial People's Hospital; Sichuan Provincial People’s Hospital, Jiangsu Hengrui Medicine Co., Ltd funded
liver cancer
 
 
ChiCTR1800017789: A real world major data study for Apatinib in the treatment of advanced gastric cancer

Not yet recruiting
4
1000
 
Apatinib
Zhejiang Provincial Hospital of TCM, Zhejiang Cancer Hospital; Zhejiang Provincial Hospital of TCM, self-financing
advanced gastric cancer
 
 
ChiCTR1900021506: Therapeutic effect of apatinib monotherapy on recurrence and persistent cervical squamous cell carcinoma due to failure of chemoradiotherapy or other targeted therapy and correlation research between the efficacy of apatinib and the angiogenesis immune response subtype gene

Not yet recruiting
4
40
 
Apatinib monotherapy
Chongqing Cancer Hospital; Chongqing Cancer Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd.
Cervical squamous cell carcinoma
 
 
ChiCTR1900020825: One-arm, open clinical study of apatinib mesylate combined with EGFR-TKI in the treatment of advanced non-squamous cell lung cancer patients with EGFR gene mutation

Not yet recruiting
4
120
 
apatinib combined with EGFR-TKI
Affiliated Hospital of Inner Mongolia Medical University; Affiliated Hospital of Inner Mongolia Medical University, Self financing
lung cancer
 
 
ChiCTR1800015057: Third-line therapy with apatinib in metastatic colorectal cancer: individualized dose adjustment based on plasma concentration and adverse reactions

Recruiting
4
36
 
apatinib
West China Hospital, Sichuan University; West China Hospital, Sichuan University, Self financing
Metastatic colorectal cancer
 
 
ChiCTR1800015920: Efficacy and safety of apatinib combined with pemetrexed plus platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer

Completed
4
40
 
apatinib 250mg Qd combined with chemotherapy ;apatinib 500mg Qd combined with chemotherapy
National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Cancer Foundation of China, Terry Fox Run, Marathon of Hope
Non-squamous non-small cell lung cancer
 
 
ChiCTR1800015764: Single arm, open, prospective study low dose of Apatinib in the treatment of primary and recurrent high grade gliomas

Recruiting
4
30
 
apatinib + Temozolomide + radiotherapy
Gansu Province Cancer Hospital; Gansu Province Cancer Hospital, raise independently
primary and recurrent high grade gliomas
 
 
ChiCTR-OPC-17011039: Apatinib and radiofrequency ablation treatment with lung cancer

Recruiting
4
30
 
Apatinib+ RFA
Sir Run Run Shaw Hospital; Sir Run Run Shaw Hospital, self-financing
lung cancer
 
 
ChiCTR1800016501: Apatinib combined with pemetrexed plus cisplatin as the first-line treatment of patients with negative diver gene advanced non-squamous non-small cell lung cancer: a single - center and single - arm clinical study

Recruiting
4
20
 
apatinib
Affiliated Hospital of Shandong Academy of Medical Sciences; Affiliated Hospital of Shandong Academy of Medical Sciences, self financing
negative diver gene advanced non-squamous non-small cell lung cancer
 
 
ChiCTR1800017225: Clinical study of apatinib mesylate combined with paclitaxel in second-line and second-line maintenance of advanced gastric cancer

Recruiting
4
60
 
apatinib mesylate combined with paclitaxel
Jiangxi Tumor Hospital; Jiangxi Tumor Hospital, Jiangsu hengrui pharmaceutical co. LTD
gastric cancer
 
 
ChiCTR1900020699: Randomized controlled prospective trial for apatinib mesylate combined with TACE in the treatment of advanced hepatocellular carcinoma

Recruiting
4
120
 
TACE+Oral administration of apatinib at 500mg/ day ;Only TACE
The First Affiliated Hospital of Nanchang University; The First Affiliated Hospital of Nanchang University, At his own expense
liver cancer
 
 
ChiCTR-OPN-16008694: Clinical study of Apatinib Mesylate Tablets unite Docetaxel in the Second-line treatment of EGFR Wild-type Advanced Non-Squamous Non-Small Cell Lung Cancer

Not yet recruiting
4
55
 
Apatinib and docetaxel
Huizhou People's Hospital; Huizhou People's Hospital, self-financing
EGFR Wild-type Advanced Non-Squamous Non-Small Cell Lung Cancer
 
 
ChiCTR1800017424: Mesylate tablets of apatinib as first-line treatment of metastatic soft tissue sarcoma, randomized, crossover, multi center clinical study

Recruiting
4
80
 
IFO+EPI regimen ;Pan apatinib scheme
General Hospital of Shenyang Military Area Command; General Hospital of Shenyang Military Area Command, Self-raising
metastatic soft tissue sarcoma
 
 
ChiCTR1800016529: A prospective, open label, randomized, controlled trial for evaluation of the safety and efficacy of Apatinib mesylate tablets combined with docetaxel in the treatment of metastatic breast cancer

Recruiting
4
130
 
Apatinib Mesylate Tablets versus Docetaxel combined with Docetaxel
Breast center of Jiangxi Tumor Hospital; Level of the institution:, Self financing
breast cancer
 
 
ChiCTR1800018642: An exploration of Apatinib Plus IP solution as 2nd Line Treatment in Patients With Small Cell Lung Cancer

Recruiting
4
30
 
apatinib mesylate combined with IP chemotherapy
Affiliated Cancer Hospital of Harbin Medical University; Affiliated Cancer Hospital of Harbin Medical University, By oneself
Non-small Cell Lung Cancer
 
 
ChiCTR1800017537: One-arm, single-center, open-label clinical study of concurrent chemoradiotherapy combined with adjuvant chemotherapy and antiangiogenic therapy for advanced malignant tumors

Not yet recruiting
4
30
 
Apatinib monotherapy or apatinib combined with other drugs
Chongqing Cancer Hospital; ChongQing Cancer Hospital, Jiangsu hengrui pharmaceutical co. LTD
advanced malignant solid tumors
 
 
ChiCTR1800017333: Therapeutic effect of transcatheter arterial chemoembolization(TACE) combined with anti-angiogenesis therapy on patients with liver cancer

Not yet recruiting
4
20
 
TACE+Apatinib
The Second Affiliated Hospital of Chongqing Medical University; The Second Affiliated Hospital of Chongqing Medical University, Jiangsu Hengrui Pharmaceutical co. LTD
Hepatocellular carcinoma
 
 
ChiCTR1800017375: Observational clinical study of apatinib for advanced malignant solid tumors

Recruiting
4
30
 
Apatinib monotherapy or apatinib combined with other drugs
The First Hospital Affiliated to AMU/Southwest Hospital; The First Hospital Affiliated to AMU/Southwest Hospital, Jiangsu hengrui pharmaceutical co. LTD.
advanced malignant solid tumors
 
 
ChiCTR1800017511: Study on the maintenance of apatinib and the administration of apatinib in patients with primary liver cancer after TACE treatment

Recruiting
4
40
 
Apatinib monotherapy for maintenance after TACE treatment
Chongqing Cancer Hospital; Chongqing Cancer Hospital, Jiangsu hengrui pharmaceutical co. LTD
Hepatocellular carcinoma that cannot be resected or relapses after resection
 
 
ChiCTR1800014477: Mesylate apatinib as monotherapy or in combination with capecitabine in the treatment of advanced breast cancer multicenter, open, single arm clinical study

Not yet recruiting
4
96
 
apatinib or apatinib plus capecitabine
Sui'ning Central Hospital; Sui'ning Central Hospital, Self financing
advanced breast cancer
 
 
ChiCTR1800017494: A prospective, open-label, one-arm clinical study of pemetrexed in combination with platinum-based regimens in patients with advanced non-squamous non-small cell lung cancer treated with apatinib after 4-6 cycles of chemotherapy

Not yet recruiting
4
20
 
Apatinib monotherapy for maintenance treatment
Xinqiao Hospital, Army Medical University; XinQiao Hospital, Amy Medical University, Jiangsu hengrui pharmaceutical co. LTD
Non-scale non-small cell lung cancer
 
 
ChiCTR1800017503: Clinical study for effect and safety, as well as prognostic factors analysis of apapitatin mesylate combined with TACE in the treatment of patients with advanced hepatocellular carcinoma

Not yet recruiting
4
40
 
Apatinib monotherapy for maintenance treatment after TACE treatment
Daping Hospital, Army Medical University; DaPing Hospital, Army Medical University, Jiangsu hengrui pharmaceutical co. LTD
Advanced hepatocellular carcinoma
 
 
ChiCTR1900027247: One-arm clinical study for camrelizumab, apatinib mesylate and TACE in the treatment of advanced hepatocellular carcinoma

Recruiting
4
20
 
camrelizumab, apatinib mesylate and TACE
The First Affiliated Hospital of Suzhou University; The First Affiliated Hospital of Suzhou University, Self financing
Liver cancer
 
 
 

Download Options